The main differences were between the reference group and the clinical > biological group: the latter participants were more often positive for α-synuclein pathology, had higher NfL levels, greater TDP-43–like atrophy, and higher burden of cerebral small vessel disease lesions (all false discovery rate P < .05). Here, TARDBP is linked to cerebral small vessel disease.